Malignant hyperthermia (MH) is a hypermetabolic disorder of skeletal muscle triggered almost exclusively by potent inhalational agents and suxamethonium. Signs of an MH reaction are non-specific and may be confused with the presentation of other problems such as sepsis and overheating of a patient. A high index of suspicion is needed to be aware of an early presentation of MH. Nine patients are presented who showed abnormal signs with an earlier anaesthetic where the possible diagnosis of an MH reaction was missed. These patients either presented later with an MH reaction, confirmed by DNA analysis and in some cases in vitro contracture testing, or were diagnosed by the identification of a causative mutation confirming MH susceptibility. The MH clinical grading scale is helpful in determining the likelihood that clinical indicators indicate a possible MH reaction. Masseter muscle rigidity is a known sign of MH, confirmed in this report by positive in vitro contracture testing and DNA analysis. Several uncommon muscle disorders have a high association with MH, and postoperative myalgia unrelated to suxamethonium can be a sign which is associated with MH. These reports emphasise the importance of a thorough family history (as the MH status was known by the family in four patients), a high index of suspicion for MH, and documentation of the possibility of MH susceptibility in the anaesthesia record.
Malignant hyperthermia (MH) is an uncommon disorder of skeletal muscle, with autosomal dominant inheritance involving abnormal skeletal muscle calcium metabolism. Individuals susceptible to MH, when exposed to certain triggers, develop a hypermetabolic state characterised by hypercarbia, hyperthermia, respiratory and metabolic acidosis, and sometimes muscle rigidity and rhabdomyolysis. MH is triggered by exposure to potent inhalational anaesthetic agents and suxamethonium. Penetrance and expression are variable so that patients with the same mutation may have significantly different reactions to the same drugs. A patient may not have reacted previously even when exposed to the same anaesthetic agents 1 . Heytens et al suggest that clinical presentations of MH are becoming more insidious due to the change in inhalational agents used as well as some of the changes in anaesthetic techniques 2 .
We present a retrospective case series of nine MH susceptible patients where there had been prior exposure to triggering anaesthetics. These patients were exposed to triggering agents, and signs of MH were present but not recognised. Diagnosis was made during subsequent anaesthesia or retrospectively when another family member was diagnosed. These anaesthetics have been collated from records spanning the last 30 years and encompass various triggering agents.
Methods
Ethics approval was obtained from local hospital committees (research ID 2017.02.004). Consent was obtained for all patients. Immediate relatives gave consent for patients one and six. Suspected MH reactions were identified by clinicians involved with MH in their respective centres in both New Zealand (NZ) and Australia. Retrospective MH reactions were identified from the hospital records of these patients. For each patient, the first anaesthetic reported indicates the recognised MH reaction with the exception of patient 5. The next reports are those where a possible MH reaction occurred on an earlier occasion, followed by reports of uneventful anaesthetics.
In vitro contracture testing (IVCT) was conducted according to the European MH group protocol 3, 4 . Specimens were tested with halothane and caffeine and results divided into four categories: MHN (normal), MH Susceptible with positive responses to both halothane and caffeine (MHS hc ), and a positive response to halothane alone (MHS h ), or caffeine alone (MHS c ). The latter two categories are regarded as susceptible to MH.
DNA was extracted from whole blood using the Promega Wizard TM (Promega Corp, Madison, WI, USA) genomic DNA purification kit according to the manufacturer's instructions. Familial mutations were identified by kinetic polymerase chain reaction-amplification of RYR1 sequences from genomic DNA using high resolution amplicon melting for discrimination 5 .
Case reports

Patient 1
This 16-year-old female received an alfaxolone/ alfadolone (Althesin)/alcuronium/halothane anaesthetic for a cortical mastoidectomy in 1980. The duration of the procedure was two hours and 45 minutes. Tachycardia was noted soon after induction and remained for most of the operation (anaesthetic record not available, post mortem documentation). Towards the end of the procedure 'dark blood' was noted and she was found to be stiff and twitching after the covers were removed. Resuscitation was unsuccessful. A post mortem temperature of 42°C was recorded. Further family investigation revealed that a cousin had died of MH in another hospital. Post mortem DNA analysis many years later identified a causative mutation in RYR1 (c.14497C>T, p.His4833Tyr) 6 . Four days earlier the patient had received an anaesthetic for suction clearance of discharging otitis media. Thiopentone and suxamethonium were used for induction and intubation respectively and nitrous oxide/oxygen/halothane for maintenance. No observations were documented; however, there were cardiac irregularities intraoperatively including coupled beats that responded to lignocaine. Postoperatively the patient complained of calf pains. The duration of the procedure was 40 minutes. She had had a 20-minute procedure, ten days earlier in which halothane and suxamethonium were used without complications.
Patient 2
This patient had four triggering anaesthetics before a family history of MH was identified. At the age of 30 years, the patient had a laparotomy for ectopic pregnancy. Induction was with thiopentone and suxamethonium and severe masseter spasm occurred. Intubation was helped with atracurium and anaesthesia maintained with isoflurane. MH was considered but thought to be unlikely. The procedure lasted one hour 25 minutes. On discussion with the family postoperatively, it was revealed that there was a family history of MH. Subsequent IVCT was MHS hc and later a causative mutation was identified (c.14477C>T, p.Thr4826Ile) 7 .
The patient had experienced three previous documented episodes of masseter spasm. In each of the episodes anaesthesia was induced with thiopentone and intubation attempted with suxamethonium. Anaesthesia was maintained with halothane for two procedures for laparoscopy, and the third with isoflurane for a laparotomy. Duration of anaesthesia was 30 minutes, 30 minutes and 1 hour 20 minutes respectively. The anaesthetic record included comments on ventricular bigeminy intraoperatively during the third anaesthetic and a mild increase in pulse rate (60 to 95 /minute). The patient awoke hyperventilating. The patient also complained of postoperative myalgia. No other abnormal recordings were documented. There was no follow-up of these three episodes of masseter spasm. All four anaesthetics were between 1985 and 1990.
Patient 3
In 1989, this 23-year-old male developed a fulminant MH reaction during an anaesthetic for stabilisation of his cervical spine following trauma. Induction agents included thiopentone, suxamethonium and pancuronium. Anaesthesia was maintained with isoflurane, oxygen and nitrous oxide. The procedure lasted over three hours, and the first evidence of MH was an SpO 2 of 88% and a tachycardia of 110 /minute, two hours and forty-five minutes into the case. Arterial blood gases (ABG) were taken; PaCO 2 was measured at 170 mmHg and temperature recorded at 40.2°C with PaO 2 54 mmHg. He developed ventricular tachycardia which required three attempts at cardioversion. Dantrolene 600 mg was administered and he survived. Subsequently a strong family history of MH was revealed and a causative mutation identified (c.14477C>T, p.Thr4826Ile). Two weeks prior to this anaesthetic the patient had undergone an anaesthetic for placement of halo fixation after his initial accident. Anaesthetic agents were thiopentone, fentanyl, and suxamethonium for intubation; halothane, oxygen and nitrous oxide were used for maintenance, and atracurium was administered for muscle relaxation. There was no end-tidal carbon dioxide (ETCO 2 ) or temperature monitoring. Twenty minutes into the procedure he became progressively tachycardic and simultaneously the systolic blood pressure dropped. The heart rate (HR) peaked at 118 /minute and the lowest recorded systolic blood pressure (SBP) was 80 mmHg. An ABG 35 minutes into the operation showed pH 7.09, PaCO 2 84.1 mmHg, and base deficit (BD) of 7.3 mmol/l. Anaesthesia ended after 50 minutes and there were no complications. The reason for the ABG was uncertain, as this was not documented in the anaesthesia record. There was no documentation of a family history of MH and no mention of possible MH was passed on to the anaesthetist two weeks later.
Patient 4
This patient had surgery for a meatoplasty at age 10 in 2002. He had a gaseous induction with sevoflurane. Intubation was facilitated with vecuronium and anaesthesia maintained with isoflurane. Forty-five minutes into the procedure the ETCO 2 had increased to 55 mmHg despite increased ventilation, and a HR of 110 /minute was recorded. Thirty minutes later ETCO 2 was recorded at 90 mmHg and temperature recorded at 38.8°C. An ABG showed pH 7.07, PaCO 2 95 mmHg and BD 4.8 mmol/l. MH was diagnosed, dantrolene was administered and the patient survived. Further family investigation revealed a history of MH. He had a positive IVCT and DNA analysis (c.14497C>T, p.His4833Tyr).
Sixteen months prior to the above operation in 2001, at nine years of age the patient had a general anaesthetic of three hours duration, also for a meatoplasty. Anaesthesia was induced with thiopentone and fentanyl and rocuronium assisted intubation. Anaesthesia was maintained with isoflurane/nitrous oxide/oxygen. The first two hours postinduction were unremarkable. Over the next 45 minutes the HR increased from 96 to 120 /minute, and ETCO 2 increased to 90 mmHg with spontaneous ventilation. Temperature was recorded at 37.8°C. The procedure finished soon after, but in the post-anaesthesia care unit (PACU) the HR remained at 120 /minute for 30 minutes, temperature increased to 38.3°C and respiratory rate to 20 /minute. The fever had settled after a further hour without further intervention. The child was discharged well and no further anaesthetic follow-up was arranged. He had had two previous anaesthetics and no abnormalities were recorded with either.
Patient 5
This 43-year-old patient had a family history of MH which was only recognised when her cousin had an MH reaction in 2011. DNA analysis in 2012 confirmed a causative mutation (c.14497C>T, p.His4833Tyr). She had undergone two previous general anaesthetics. One anaesthetic, of 20 minutes duration, was uneventful. An elective laparotomy for pyeloplasty was performed at age 34 in 2003. Anaesthesia was induced with propofol and alfentanil and maintained with desflurane throughout with a remifentanil infusion. Two-and-a-half hours into the operation her temperature had increased from 36.3°C to 37.4°C and forced air warming was stopped. It is unclear if any other cooling measures were taken. However, her temperature continued to rise over the next hour, peaking at 38.2°C, at which point surgery and anaesthesia ended. Simultaneously a rise in ETCO 2 was documented, peaking at 58 mmHg, two hours and 15 minutes into the operation. No tachycardia was documented. Her PACU notes recorded her temperature on arrival of 37.9°C, slowly resolving over the next two-and-a-half hours to 36.9°C on discharge.
Patient 6
A 39-year-old female had a fulminant MH reaction during a gastric bypass procedure in 2003. Anaesthesia was induced with propofol and maintained with sevoflurane. An increase in ETCO 2 despite increased minute ventilation, and increasing pyrexia, led to a diagnosis of suspected MH reaction two hours into the procedure. Dantrolene was administered. Subsequent IVCT was MHS hc , confirmed by identification of a causative mutation (c.14497C>T, p.His4833Tyr).
At the age of 18 years (1982) she had a general anaesthetic for a laparoscopy. Anaesthesia was induced with Althesin followed by suxamethonium (two 50 mg doses) for intubation. Anaesthesia was maintained with halothane/ nitrous oxide/oxygen. The procedure duration was 20 minutes. The anaesthetic chart was annotated with the comment "good 'twitch' but very poor relaxation".
There were no documented vital signs intraoperatively. In the PACU the temperature was recorded at 37.3°C, (preoperative 36.0°C). Her HR was recorded at 160 /minute from a baseline of 80 /minute preoperatively. On return to the ward, nursing notes comment that she was "sweating profusely and complained of feeling very hot", and HR was recorded at 96 /minute. The patient made a subsequent uneventful recovery.
The patient also received two other anaesthetics before the age of 18 for nasal surgery. Halothane was administered for both. During one procedure, she developed an arrhythmia (unspecified in the notes), which eventually settled with a beta-blocker. No problems were reported with the other anaesthetic.
Patient 7
In 2005, at the age of 14, this patient had a colonoscopy for identification and treatment of colonic polyps resulting from Peutz-Jaeger syndrome. Anaesthesia was induced with sevoflurane and fentanyl and maintained with sevoflurane. He immediately became tachypnoeic, and developed a tachycardia of 120 /minute and an ETCO 2 of 50 mmHg. Following the 20-minute procedure he was noted to be sweating and in the PACU his temperature was recorded at 40.2°C, and an ABG showed pH 7.02, pCO 2 100 mmHg, BD 8 mmol/l. MH was suspected and 140 mg dantrolene was administered. The patient's creatine kinase (CK) peaked at 5000 IU/l and his urine was positive for myoglobin. He tested MHS in 2006 and the muscle biopsy showed histological evidence of central core disease (CCD). A causative RYR1 mutation has subsequently been identified (c.7304G>A, p.Arg2435His).
Five years prior to this episode the patient was anaesthetised for a wrist fracture manipulation. He was induced with propofol, fentanyl and suxamethonium. He developed severe masseter spasm and the anaesthetist was unable to intubate so the case proceeded with bag-mask ventilation. Tympanic temperature was 37.6°C, there was no ETCO 2 rise, and heart rate rose to 120 /minute. No followup was undertaken. He subsequently had further general anaesthetics for colonoscopy where volatile was only used for induction with no reported problems with anaesthesia.
Patient 8
This patient was diagnosed at age 12 in 2008 with MH susceptibility with a positive DNA (c.14206G>A, p.Arg4737Gln)8. She had an inhalational induction with sevoflurane, oxygen and nitrous oxide for a dental procedure. Sevoflurane and fentanyl were used for maintenance and vecuronium for muscle relaxation. It was noted that she was sweaty after induction. The ETCO 2 quickly rose to 77 mmHg peaking at 100 mmHg after about 20 minutes. A temperature of 38.8°C was recorded. The volatile anaesthetic was turned off, she was hyperventilated with 100% oxygen, and dantrolene 2.5 mg/kg was administered. Over 30 minutes her observations returned to normal. She was sent to the intensive care unit for observation and made an uneventful recovery. The peak CK was 15,588 IU/l recorded at 24 hours.
The patient had two previous anaesthetics with triggering agents and developed symptoms suggestive of MH, which were attributed to stormy inductions. At age nine the patient underwent dental restorations and extractions with a gas induction with sevoflurane and maintenance with isoflurane. No suxamethonium was administered. Propofol, vecuronium and fentanyl were also given. The patient's temperature increased from 36.0°C preoperatively to 38.5°C intraoperatively. Her HR was 125 to 128 /minute throughout the operation, which was of 25 minutes duration. Her ETCO 2 remained above 55 mmHg throughout the operation, with a peak of 59 mmHg 20 minutes post-induction. The anaesthetic notes document that the ETCO 2 improved once spontaneous respiration resumed. In the PACU, the patient complained of being 'stiff' and was noted to be clammy and sweating. Her temperature was 36.8°C and respiratory rate (RR) increased to 24 /minute. MH was considered by the anaesthetist. However, it was considered unlikely as the anaesthetic was quite short, with rapid resolution of fever and tachycardia.
At age eight, the patient had a gas induction for an orthopaedic procedure with sevoflurane induction then maintenance with isoflurane for 15 minutes before changing over to a propofol infusion as her temperature was recorded at 38.6°C, HR 105 /minute, BP 90/60 mmHg with an ETCO 2 of 80 mmHg. After conversion to a propofol infusion, her temperature remained at 38.6°C, decreasing to 37.8°C after the tourniquet was released, 70 minutes after induction. The temperature then increased to 38.0°C before the operation ended 20 minutes later. Her SBP remained between 105 and 120 mmHg. Oxygen saturations were 99% on FiO 2 of 0.3, falling to 95% following tourniquet release. In the PACU the patient's temperature was initially 37.5°C, with a HR of 101 /minute, RR of 36 /minute on a T-piece with 6 litres/minute of oxygen and saturations of 94%. Further respiratory support improved SpO 2 to 100% and her temperature was recorded at 37.0°C an hour or so later. There was no referral for a possible MH reaction.
Patient 9
This patient was diagnosed with MH at the age of 33 years during a laparoscopic procedure for a ruptured ectopic pregnancy in 2011. The anaesthetic included triggering agents suxamethonium and sevoflurane. Clinical signs were tachycardia, increased ETCO 2 (72 mmHg) and temperature 39.3°C. Subsequent DNA analysis identified a causative mutation (c.14497C>T, p.His4833Tyr). This eliminated the need for IVCT.
At age 31, the patient had a general anaesthetic for an emergency caesarean section. The patient received propofol for induction, suxamethonium for intubation, and anaesthesia was maintained with sevoflurane. Her temperature had increased from 36.7°C to 37.6°C at 50 minutes post-induction with a corresponding increase in ETCO 2 to 72 mmHg despite an increase in ventilation. Her HR peaked at 130 /minute 30 minutes post-induction and remained at this rate. It was noted that she felt hot and warm in the PACU. Tachycardia of 110 /minute was noted during a previous anaesthetic of 70 minutes duration in which triggering agents were used, but there was no other evidence of MH.
Discussion
This series of MH reactions between the late 1980s to 2011 have been identified retrospectively. Test results are summarised in Table 1 .
Before dantrolene was introduced, the mortality of MH was 84% 9 . Following the use of dantrolene, as well as improved monitoring and education, mortality has reduced but has still been reported as 9% 10 . One fatal reaction is presented in this small series, but there were warning signs during her previous anaesthetics. The main aim of this paper is to indicate that a high index of suspicion of MH susceptibility should be maintained when administering triggering anaesthetics.
Signs that may indicate MH
Masseter muscle rigidity (MMR) was present in two cases and is a well-recognised early sign of MH 11 . A recent review showed that 25% of suspected MH reactions present with MMR 12 . Analysis of local data showed that other signs of MH may only be present in about 30% of cases of MMR, partly because triggering anaesthesia may be withdrawn and either the procedure abandoned or anaesthesia changed to total intravenous anaesthesia (TIVA) (unpublished data, NP). Current recommendations advise termination of the procedure if possible 4 and referral for further investigation 13 . Early signs of MH include raised ETCO 2 , tachycardia, pyrexia, arrhythmias and later rhabdomyolysis and muscular rigidity 11 . The MH Clinical Grading Scale (MHCGS) was developed to improve prediction of MH susceptibility 14 ( Table 2 ). The scale ranks the likelihood that an adverse anaesthetic event indicates MH. Clinical indicators are scored and then ranked and the ranking gives a likelihood that the event was an MH reaction. Ranking ranges from 'almost never' to 'almost certain' MH. Each of the retrospective events was analysed using the MHCGS. They ranked from 'somewhat less than likely' to 'very likely' (Figure 1 ). The signs presented here were not necessarily dramatic, but increasing ETCO 2 despite increased ventilation, increasing tachycardia, and temperature rise should be warning signs of a possible MH reaction. Seven of these retrospective presentations were from NZ indicating that about 8% of MH reactions in this country have been preceded by unrecognised events Points are awarded for each of the clinical indicators. The points are then summed to produce a raw score. A ranking is produced (1-6), which gives the likelihood that the event is a malignant hyperthermia (MH) reaction 14 . before definitive diagnosis; although this is likely to be a conservative figure as many older anaesthetic records were not available. Postoperative myalgia, particularly in the lower limbs, was present in three of our cases. This may be an overlooked but important sign in a patient with an MH reaction 15 . Myalgia has been present in 23% of NZ MH reactions and is unrelated to the use of suxamethonium (unpublished data, TB). Myalgia appears to be particularly prominent in the calf muscles and this has been apparent in recent MH reactions. MH-related myalgia appears to differ from muscle pain due to suxamethonium, which is commonly attributed to the neck, shoulder and upper abdominal muscles 16 . Generalised rigidity was present in 29% of MH reactions, but only 50% of patients experiencing myalgia postoperatively had this sign. When measured, CK was increased in 93%, although measurements >2000 IU/l (indicating rhabdomyolysis) were only present in 72% of patients with myalgia 8 . The time course of increased CK and myoglobin has been described and extreme elevation of CK has been associated with MH reactions 17, 18 .
Cardiac arrhythmias are a feature of an MH reaction, particularly atrial and ventricular ectopics, nodal tachycardia, bigeminal arrhythmia, and less commonly ventricular tachycardia 9 . Britt and Kalow reported arrhythmias in 36% of reactions 15 . This is consistent with the NZ experience where up until 1991, 35% of MH reactions included arrhythmias (unpublished data, TB). Halothane and suxamethonium were the principal triggering agents at this time. With the phasing out of halothane, arrhythmias have been noted infrequently, occurring only with isoflurane. In total, cardiac arrhythmias have developed in 21% of NZ MH reactions (unpublished data, TB), consistent with the finding of Riazi et al 12 . A cardiac arrhythmia, particularly in a younger person, although uncommon may be an early warning sign of an MH reaction.
Relevance of family history and record keeping
The family history of MH was known by the patient in cases 1,2,3 and 4. Failure to obtain an accurate family history can have fatal consequences 9, 10 . In our hospital in NZ, the electronic anaesthesia record system has included a module related to MH. Entry of data cannot progress until this module has been completed. This helps to ensure that the family history of a patient is accurately taken and in particular screened for MH. Other checks include screening the operating theatre list for susceptible patient names, screening at pre-assessment clinics, and making sure susceptible patients are aware of a family history of MH and its importance.
Review of older anaesthetic records showed that while there was significant comment about adverse events such as arrhythmia and masseter spasm, few vital signs were recorded. This study shows there was no follow-up in most instances, even when there had been significant physiological abnormalities. Electronic records with a printout after the procedure has been completed have very accurate documentation of vital signs and other data. Unfortunately, clinicians tend not to add comments to these digital records. In the cases reported, the fact that everything settled down during the recovery phase seemed to satisfy the clinicians involved. The tick-box approach these records engender, means useful information is often not documented.
For many anaesthetists, the tendency is to confine anaesthetic practice to the operating theatre environment. While a patient may stay extra time in a PACU for tachycardia and temperature to settle, once this has resolved the anaesthetist no longer has direct responsibility for the patient. It is important that anaesthetists clearly document adverse events and ensure there is appropriate follow-up. Two patients in this series had repeat anaesthetics within a short period but the significance of events was not appreciated and a major MH crisis occurred. Discussion with an MH expert is helpful if an anaesthetist is uncertain of the significance of abnormal signs. Arterial blood gases or measurement of creatine kinase can help confirm or exclude a likely MH diagnosis.
Abortive reactions (e.g. the reaction settling after withdrawal of the volatile, cooling, or just settling at the end of the anaesthetic following close observation but no dantrolene administered) have been described 1, [19] [20] [21] [22] . Only 56% of NZ reactions have received dantrolene. Similarly, data from two Australian units showed dantrolene was administered in 51% and 59% of MH reactions (unpublished data-RG, NS). Abortive MH events are difficult to diagnose. When everything settles down, the tendency is to accept that there was nothing wrong. Fulminant MH is less common with modern volatile agents, and switching to TIVA and increasing ventilation can hide the slower onset of MH. This occurred in case 9, where MH was considered but thought to be unlikely and the patient had fulminant MH three years later. Previous uneventful anaesthetics with triggering anaesthetics do not eliminate MH susceptibility. On average, MH susceptible patients have two uneventful anaesthetics before triggering with a third 23 .
We present nine retrospective events in five families. Five reactions presented in one family alone. The p.His4833Tyr mutation is the commonest mutation in NZ (unpublished data, KS). There are two very large MH susceptible families in NZ, with more than 2,000 members documented in one family alone. Nine generations have been documented in this one family, six in another. Communication between family members does not always happen, particularly between family members distantly related. If there is a possible family history or an individual possibility of MH susceptibility, either a trigger-free anaesthetic can be used or anaesthesia delayed while relatives are contacted to determine if the patient has a blood relationship to the family.
CCD is a congenital myopathy with sarcomere disorganisation resulting in a lack of mitochondria and oxidative enzyme activity of the myofibre. Hypotonia in infancy and delayed motor development are characteristic. The disorder may or may not be progressive throughout life. There is a strong association with MH. CCD is associated with both autosomal dominant and recessive mutations in the ryanodine receptor gene (RYR1). Some mutations can be common to both disorders, but others may cause either CCD or MH. An individual with CCD or a family history of CCD should be regarded as susceptible to MH unless IVCT demonstrates an MHN diagnosis. Offspring of an MHN patient will not be susceptible to MH 24 but may still inherit CCD. Other rare muscle disorders may be associated with MH including King-Denborough syndrome 25 , multi-minicore disease 26 , centronuclear myopathy 27 and congenital fibre type disproportion myopathy 28, 29 .
In summary, although anaesthetic practice and agents have changed with time, these cases highlight the importance of a thorough family history, clear documentation and a high index of suspicion for MH. There should be follow-up, with consideration of referral to an MH centre, whenever there are perioperative concerns about potential MH.
